journal article·2025-11-25Open access

The Ballet of Natural-Product: Carrier-Free “Triadic” Drug Delivery Platforms for Enhanced Tumor Treatment

Liyan Yang, Zhonglei Wang

Journal of Functional Biomaterials· Volume 16· Issue 12

Abstract

Cancer poses a considerable challenge to global public health and stands as the second leading cause of mortality worldwide. Chemotherapy provides limited benefits for advanced-stage cancer, mainly due to high systemic toxicity and drug resistance. Optimal cancer treatment requires a sophisticated, multidisciplinary collaboration aimed at extending survival, enhancing quality of life, and reducing toxicity. Natural products present advantages, including a wide array of structural diversity, reduced toxicity, improved immune modulation, and the ability to act on multiple targets. Nanomedicine design shows promise in tumor treatment and diagnosis by improving efficacy and minimizing side effects. Due to the heterogeneity of tumors in genetics, metabolism, and microenvironment, natural product-based carrier-free drug delivery platforms have been actively investigated and demonstrated considerable potential for enhanced tumor treatment. “Triadic” strategies can simultaneously perform various functions on a carrier-free intelligent nanoplatform. These include combinational chemotherapy, photodynamic therapy (PDT) with bioimaging and chemotherapy, PDT combined with photothermal therapy (PTT) and chemotherapy, chemo-radio-theranostics, as well as gene therapy (GT) in conjunction with PTT and chemotherapy. This multifaceted approach enhances therapeutic efficacy, reduces multidrug resistance, and minimizes systemic toxicity. This review encompasses recent advancements in cancer therapy using carrier-free “triadic” nanomedicines based on natural products (between 2024 and 2025) and evaluates this evolving field, emphasizing the pivotal role of natural products—berberine, camptothecin, hypericin, erianin, curcumin, lactose, paclitaxel, gambogic acid, and glycyrrhizic acid—in drug delivery platforms. Furthermore, it addresses the challenges and bottlenecks encountered by carrier-free drug delivery platforms, offering valuable insights into their development trajectories.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Curcumin's Biomedical Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Physics and Physical Engineering, Qufu Normal University, Qufu 273165, China

Beijing National Laboratory for Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China

Key Laboratory of Green Natural Products and Pharmaceutical Intermediates in Colleges and Universities of Shandong Province, School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu 273165, China

Key Laboratory of Bioorganic Phosphorous Chemistry and Chemical Biology, School of Pharmaceutical Sciences, Tsinghua University, Beijing 100084, China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Shandong Province · PhD Research Start-up Foundation of Qufu Normal University

References (100+)

Show source-provided references
1. Cancer treatment survivorship statistics 2025: An urgent call to optimize health after cancer
2. Cancer drug resistance: An evolving paradigm10.1038/nrc3599 ↗
3. Rising above: Exploring the therapeutic potential of natural product-based compounds in human cancer treatment10.53388/TMR20240618001 ↗
4. Ovarian tumor microenvironment contributes to tumor progression and chemoresistance
5. The multidrug resistance transporter P-glycoprotein confers resistance to ferroptosis inducers10.20517/cdr.2023.29 ↗
6. Wang, Z., Sun, X., Sun, M., Wang, C., and Yang, L. (2025). Game changers: Blockbuster small-molecule drugs approved by the FDA in 2024. Pharmaceuticals, 18.10.3390/ph18050729 ↗
7. Therapeutic potential of oncolytic viruses in the era of precision oncology
8. Artificial intelligence in clinical trials of lung cancer: Current and future prospects10.1016/j.intonc.2024.11.003 ↗
9. Integration of artificial intelligence in clinical laboratory medicine: Advancements and challenges10.1002/INMD.20230056 ↗
10. Systemic metastasis-targeted nanotherapeutic reinforces tumor surgical resection and chemotherapy10.1038/s41467-021-23466-5 ↗
11. Contemporary radiotherapy: Present and future10.1016/S0140-6736(21)00233-6 ↗
12. Unlocking the potential of immunotherapy in platinum-resistant ovarian cancer: Rationale, challenges, and novel strategies
13. Oncogenic viral antigens for engineered T cell immunotherapy: Challenges and opportunities10.1002/med4.37 ↗
14. HER3-targeted therapy: The mechanism of drug resistance and the development of anticancer drugs
15. Yang, L., and Wang, Z. (2021). Natural products, alone or in combination with FDA-approved drugs, to treat COVID-19 and lung cancer. Biomedicines, 9.10.3390/biomedicines9060689 ↗
16. Thao, L.T.P., Nguyen, T., and Singh, J. (2025). Low-dose aspirin for individualized cancer prevention in older adults: A secondary analysis of the ASPREE randomized clinical trial. JAMA Oncol.10.1001/jamaoncol.2025.3593 ↗
17. Adeno-associated virus vectors for gene therapy—Focusing on melanoma10.1002/INMD.20240031 ↗
19. Current applications of tumor local ablation (TLA) combined with immune checkpoint inhibitors in breast cancer treatment
20. Kalayil, N., Budar, A.A., and Dave, R.K. (2024). Nanofibers for drug delivery: Design and fabrication strategies. BIO Integr., 5.10.15212/bioi-2024-0023 ↗
21. Overcoming drug resistance through extracellular vesicle-based drug delivery system in cancer treatment
22. Bench-to-bedside translation of podophyllotoxin-based nanomedicines for cancer treatment: Utopias and reality?10.20517/microstructures.2025.71 ↗
23. Recent advances in natural compounds inducing non-apoptotic cell death for anticancer drug resistance10.20517/cdr.2023.78 ↗
24. New mechanisms of multidrug resistance: An introduction to the cancer drug resistance special collection10.20517/cdr.2023.86 ↗
25. Barriers in access to oncology drugs—A global crisis10.1038/s41571-022-00700-7 ↗
26. Butler, M.S., Capon, R.J., Blaskovich, M.A., and Henderson, I.R. (2025). Natural product-derived compounds in clinical trials and drug approvals. Nat. Prod. Rep.10.1039/D5NP00031A ↗
27. Wang, Z., and Yang, L. (2020). Turning the tide: Natural products and natural-product-inspired chemicals as potential counters to SARS-CoV-2 infection. Front. Pharmacol., 11.10.3389/fphar.2020.01013 ↗
28. Natural products in drug discovery: Advances and opportunities10.1038/s41573-020-00114-z ↗
29. Wang, Z., and Yang, L. (2023). The therapeutic potential of natural dietary flavonoids against SARS-CoV-2 infection. Nutrients, 15.10.3390/nu15153443 ↗
30. Therapeutic effects of Chinese herbal medicines for treatment of urolithiasis: A review
31. Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China10.1016/j.ejmech.2023.115503 ↗
32. Baicalin: A prominent therapeutic agent against colorectal cancer10.53388/TMR20220901001 ↗
33. Highly oxygenated dihydrostilbenoids and flavones from the aerial part of Glycyrrhiza uralensis and their antimicrobial activities10.1097/st9.0000000000000048 ↗
34. Wang, Z. (2019). Advances in the asymmetric total synthesis of natural products using chiral secondary amine catalyzed reactions of α,β-unsaturated aldehydes. Molecules, 24.10.3390/molecules24183412 ↗
35. Advances in the chemical synthesis of artemisinin10.1080/00397911.2014.884225 ↗
36. Ragozzino, C., Casella, V., Coppola, A., Scarpato, S., Buonocore, C., Consiglio, A., Palma Esposito, F., Galasso, C., Tedesco, P., and Della Sala, G. (2025). Last decade insights in exploiting marine microorganisms as sources of new bioactive natural products. Mar. Drugs, 23.10.3390/md23030116 ↗
37. Chinese herbal medicines for prostate cancer therapy: From experimental research to clinical practice
38. Natural product-induced oxidative stress-synergistic anti-tumor effects of chemotherapeutic agents10.53388/TMR20230626001 ↗
39. Integrating tradition and innovation: Health industry opportunities for ginseng with foods and medicines
40. Microbial transformation of some simple isoquinoline and benzylisoquinoline alkaloids and in vitro studies of their metabolites10.1016/j.phytochem.2021.112828 ↗
41. Traditional Chinese medicines for non-small cell lung cancer: Therapies and mechanisms
42. Clinical antitumor application and pharmacological mechanisms of Dahuang Zhechong Pill
43. Co-assembly strategies of natural plant compounds for improving their bioavailability10.26599/FMH.2025.9420022 ↗
44. Magnolol and 5fluorouracil synergy inhibition of metastasis of cervical cancer cells by targeting PI3K/AKT/mTOR and EMT pathways
45. Jahangiri, R. (2025). Natural products and derivatives hold promise to improve treatment of unresponsive tumours. Nat. Prod. Res., 1–20.10.1080/14786419.2025.2505603 ↗
46. Wu, K., Kwon, S.H., Zhou, X., Fuller, C., Wang, X., Vadgama, J., and Wu, Y. (2024). Overcoming challenges in small-molecule drug bioavailability: A review of key factors approaches. Int. J. Mol. Sci., 25.10.3390/ijms252313121 ↗
47. Natural products: A lead for drug discovery and development10.1002/ptr.7099 ↗
48. Theanine combined with cisplatin inhibits the proliferation and metastasis of TNBC cells through Akt signaling pathway10.53388/TMR20221025001 ↗
49. Wu, J., Li, Y., He, Q., and Yang, X. (2023). Exploration of the use of natural compounds in combination with chemotherapy drugs for tumor treatment. Molecules, 28.10.3390/molecules28031022 ↗
50. Combination of photothermal, prodrug and tumor cell camouflage technologies for triple-negative breast cancer treatment10.1016/j.mtadv.2021.100199 ↗
51. Bargakshatriya, R., and Pramanik, S.K. (2023). Stimuli-responsive prodrug chemistries for cancer therapy. ChemBioChem, 24.10.1002/cbic.202300155 ↗
52. Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system10.20517/cdr.2023.16 ↗
53. Nano-drug delivery systems based on natural products10.2147/IJN.S443692 ↗
54. Drug delivery of natural products through nanocarriers for effective breast cancer therapy: A comprehensive review of literature10.2147/IJN.S328135 ↗
55. Recent advanced lipid-based nanomedicines for overcoming cancer resistance
56. Acquisition of drug resistance in endothelial cells by tumor-derived extracellular vesicles and cancer progression
57. Natural-product-based, carrier-free, noncovalent nanoparticles for tumor chemo-photodynamic combination therapy10.1016/j.phrs.2024.107150 ↗
58. Recent advances in carrier-free natural small molecule self-assembly for drug delivery10.1039/D4BM01153H ↗
59. Li, G., Cai, C., Zhang, N., Wang, Z., Zhang, M., Liu, Q., Chen, S., Shang, Y., Zhao, C., and Ren, S. (2025). Carrier-free procyanidin-ferric nanonetworks loading gefitinib to inhibit TMEM16A-EGFR mutual activation loop for photothermally enhanced breast cancer targeted therapy. Mater. Today Bio, 35.10.1016/j.mtbio.2025.102426 ↗
60. Nanomedicine based on natural products: Improving clinical application potential10.1155/2022/3066613 ↗
61. Carrier-free nanomedicines for cancer treatment10.1016/j.pmatsci.2021.100919 ↗
62. An, J., Zhang, Z., Zhang, J., Zhang, L., and Liang, G. (2024). Research progress in tumor therapy of carrier-free nanodrug. Biomed. Pharmacother., 178.10.1016/j.biopha.2024.117258 ↗
63. Carrier-free supramolecular nanomedicines assembled by small-molecule therapeutics for cancer treatment10.1016/j.cclet.2022.107827 ↗
64. Multicomponent carrier-free nanodrugs for cancer treatment10.1039/D2TB02025D ↗
65. Carrier-Free Nanomedicine for Cancer Immunotherapy10.1166/jbn.2022.3315 ↗
66. Wang, Z., Song, X.Q., Xu, W., Lei, S., Zhang, H., and Yang, L. (2023). Stand up to stand out: Natural dietary polyphenols curcumin, resveratrol, and gossypol as potential therapeutic candidates against severe acute respiratory syndrome coronavirus 2 infection. Nutrients, 15.10.3390/nu15183885 ↗
67. Yang, L., and Wang, Z. (2021). Advances in the total synthesis of aflatoxins. Front. Chem., 9.10.3389/fchem.2021.779765 ↗
68. Ginsenoside Rb1 in cardiovascular and cerebrovascular diseases: A review of therapeutic potentials and molecular mechanisms
69. Advances in the total synthesis of gelsemine10.2174/1385272826666220210124835 ↗
70. Santonocito, D., Campisi, A., Pellitteri, R., Sposito, G., Basilicata, M.G., Aquino, G., and Puglia, C. (2023). Lipid nanoparticles loading steroidal alkaloids of tomatoes affect neuroblastoma cell viability in an in vitro model. Pharmaceutics, 15.10.3390/pharmaceutics15112573 ↗
71. Advances in the first total synthesis of natural flavonoids10.1080/00397911.2013.820835 ↗
72. Parodi, A., Buzaeva, P., Nigovora, D., Baldin, A., Kostyushev, D., Chulanov, V., and Zamyatnin, A.A. (2021). Nanomedicine for increasing the oral bioavailability of cancer treatments. J. Nanobiotechnol., 19.10.1186/s12951-021-01100-2 ↗
73. Enhancing drugs bioavailability using nanomedicine approach: Predicting solubility of Tolmetin in supercritical solvent via advanced computational techniques10.1016/j.molliq.2022.120103 ↗
74. Hydrophobicity: The door to drug delivery10.1002/psc.3558 ↗
75. Recent progress in nanostructured smart drug delivery systems for cancer therapy: A review10.1021/acsabm.2c00002 ↗
76. A computer-aided heterodimer-based “triadic” carrier-free drug delivery platform to mitigate multidrug resistance in lung cancer enhance efficiency10.1016/j.jcis.2024.08.100 ↗
77. Wang, X., Sun, K., Dong, J., Ge, Y., Liu, H., Jin, X., and Yu, X.A. (2025). Carrier-free nanoparticles based on natural products trigger dual "synergy and attenuation" for enhanced phototherapy of liver cancer. Mater. Today Bio, 35.10.1016/j.mtbio.2025.102278 ↗
78. Lu, Z., Wang, T., Xu, X., Hu, Q., Wang, L., and Jin, Y. (2025). Carrier-free nano-integrated strategy of phototherapy and chemotherapy for synergetic AKT targeted therapy to inhibit cancer metastasis and recurrence. J. Nanobiotechnol., 23.10.1186/s12951-025-03539-z ↗
79. Self-assembled dual-targeting nanoplatform for synergistic photodynamic and PROTAC-mediated metabolic starvation in triple-negative breast cancer10.1016/j.cej.2025.165815 ↗
80. Glycosylated AIE-active red light-triggered photocage with precisely tumor targeting capability for synergistic type I photodynamic therapy and CPT chemotherapy10.1002/anie.202413350 ↗
81. Preclinical and first-in-human study of a compact radionuclide labeled self-assembly nanomedicine for chemo-radio-theranostics of cancer10.1021/acsnano.4c18489 ↗
82. A carrier-free DNA nanoplatform for efficient three-in-one tumor therapy in vivo10.1016/j.nantod.2025.102734 ↗
83. Drug independence and the curability of cancer by combination chemotherapy10.1016/j.trecan.2022.06.009 ↗
84. Gilad, Y., Gellerman, G., Lonard, D.M., and O’malley, B.W. (2021). Drug combination in cancer treatment—From cocktails to conjugated combinations. Cancers, 13.10.3390/cancers13040669 ↗
85. cRGD-modified nanoparticles of multi-bioactive agent conjugate with pH-sensitive linkers and PD-L1 antagonist for integrative collaborative treatment of breast cancer10.1039/D2NH00590E ↗
86. Broad-spectrum prodrugs with anti-SARS-CoV-2 activities: Strategies benefits challenges10.1002/jmv.27517 ↗
87. Nano-drug co-delivery system of natural active ingredients and chemotherapy drugs for cancer treatment: A review10.1080/10717544.2022.2094498 ↗
88. Iova, V., Iova, G.M., Tiron, A.T., Scrobota, I., Vlad, S., and Tudosie, M.S. (2025). Latest achievements in the development of nanoparticle-based drug delivery systems of Pt drugs and prodrugs in cancer therapy. Pharmaceutics, 17.10.3390/pharmaceutics17101267 ↗
89. A computer-aided, carrier-free drug delivery system with enhanced cytotoxicity and biocompatibility: A universal model for multifunctional lung cancer therapy10.1016/j.colsurfb.2025.114557 ↗
90. An activatable carrier-free triple-combination nanomedicine for ALK/EGFR-mutant non-small cell lung cancer highly permeable targeted chemotherapy10.1039/D2NJ03231G ↗
91. Recent progress in photosensitizers for overcoming the challenges of photodynamic therapy: From molecular design to application10.1039/D0CS00173B ↗
92. Cell membrane biomimetic nanomedicines for cancer phototherapy10.1002/INMD.20220012 ↗
93. Screening of photosensitizers-ATP binding cassette (ABC) transporter interactions in vitro
94. Recent advances in photosensitizers as multifunctional theranostic agents for imaging-guided photodynamic therapy of cancer10.7150/thno.62479 ↗
95. Correia, J.H., Rodrigues, J.A., Pimenta, S., Dong, T., and Yang, Z. (2021). Photodynamic therapy review: Principles, photosensitizers, applications, and future directions. Pharmaceutics, 13.10.3390/pharmaceutics13091332 ↗
96. Recent strategies to develop innovative photosensitizers for enhanced photodynamic therapy10.1021/acs.chemrev.1c00381 ↗
97. Essential role of medicine and food homology in health and wellness
98. Chemical compositions health-promoting effects of Cichorium intybus, L. (chicory): A narrative review10.26599/FMH.2024.9420012 ↗
99. Advances and challenges of medicine and food homology earthworms: Active ingredients, efficacy and quality control10.1016/j.tifs.2025.105065 ↗
100. ‘Food and medicine continuum’ in the East and West: Old tradition and current regulation